CNS Pharmaceuticals, Inc. (NASDAQ:CNSP)
| Market Cap | 7.75M-49.3% |
| Revenue (ttm) | 0 |
| Net Income | -16.70M-8.0% |
| EPS | -23.59+88.4% |
| Shares Out | 1.46M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 843.612 |
| Open | 5.36 |
| Previous Close | 5.43 |
| Day's Range | 5.22 - 5.50 |
| 52-Week Range | 1.90 - 10.56 |
| Beta | 1.02 |
| Analysts | Buy |
| Price Target | 0.50(-90.57%) |
| Earnings Date | Nov 18, 2026 |
Insiders here have filed 1 Form 4 in the last 90 days, but all of them are share awards, grants or other non-market transactions. Those are compensation, not a decision to buy, so they are not scored.
About CNSP
CNS Pharmaceuticals, Inc. is a clinical-stage pharmaceutical firm primarily focused on developing innovative anti-cancer therapies for tumors affecting the brain and central nervous system. Its primary investigational compound, Berubicin, an anthracycline, is currently progressing through Phase I and II clinical trials as a potential treatment for glioblastoma multiforme, an aggressive form of brain cancer. To bolster its research and development initiatives, the company has entered into several strategic agreements. These include licensing arrangements with Houston Pharmaceuticals, Inc., The University of Texas M.D. Anderson Cancer Center, and Animal Life Sciences, LLC. Additionally, CNS Pharmaceuticals has a development agreement in place with WPD Pharmaceuticals Inc. and a collaborative partnership with Reata Pharmaceuticals, Inc. The company was founded in 2017 and is headquartered in Houston, Texas.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$CNSP stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in CNSP holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by CNSP's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
CNSP Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New CNSP patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to CNSP from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in CNSP
| ETF | Est. Holding Size |
|---|---|
| VXFVanguard Extended Market ETF | $41.89K |
Estimated from each fund’s disclosed top holdings × AUM
CNSP Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from CNSP’s recent data — informational, not investment advice